RENAsym, a QST Model to Predict Drug-Induced Kidney Injury

Authors: Hamzavi N
Conference: SMB
Software: DILIsym®, RENAsym®
Division: DILIsym Services

Introduction to RENAsym

  • Drug-induced kidney injury or acute kidney injury (AKI) is one of the major reasons for drug failure behind cardiovascular and liver injuries
  • RENAsym development was motivated by DILI-sim Initiative members
  • DILIsym services awarded a Fast-Track Small Business Innovation Research (SBIR) grant by the National Institutes of Diabetes  and Digestive and Kidney Diseases (NIDDK) to develop RENAsym
  • Spanning Summer 2018 to Fall 2021
  • Software development in final stages
  • RENAsym consortium, consisting of numerous pharmaceutical partners, formed to gather development direction and share important compounds and data

By Nader Hamzavi

Presented at SMB 2021 Annual Meeting June 13-17, 2021